Pyrimidine, quinazoline, pteridine and triazine derivatives
申请人:Binggeli Alfred
公开号:US20070225271A1
公开(公告)日:2007-09-27
This invention is concerned with compounds of the formula
wherein A, R
1
to R
5
and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
Expedient Synthesis of Quinazoline Analogues through Direct Nucleophilic Arylation/Alkylation of 2-Chloroquinazoline
作者:Yang Yang
DOI:10.1055/s-0035-1561587
日期:——
Abstract A practical approach was developed for the synthesis of 4-arylquinazoline compounds through a one-pot nucleophilic arylation/alkylation of 2-chloroquinazoline with aryl lithium compounds generated in situ, followed by ring oxidation. The obtained 2-chloro-4-arylquinazoline adducts were further used as versatile intermediates that undergo a variety of synthetic transformations to provide functionalized
摘要 已开发出一种实用的方法,该方法是通过2-氯喹唑啉与原位生成的芳基锂化合物的一锅亲核芳基化/烷基化反应,然后进行环氧化,来合成4-芳基喹唑啉化合物。所获得的2-氯-4-芳基喹唑啉加合物还用作通用中间体,该中间体经过各种合成转化以提供官能化的喹唑啉化合物。芳基化中间体二氢喹唑啉也被精制为三环二氢咪唑并[2,1- b ]喹唑啉酮。 已开发出一种实用的方法,该方法是通过2-氯喹唑啉与原位生成的芳基锂化合物的一锅亲核芳基化/烷基化反应,然后进行环氧化,来合成4-芳基喹唑啉化合物。所获得的2-氯-4-芳基喹唑啉加合物还用作通用中间体,该中间体经过各种合成转化以提供官能化的喹唑啉化合物。芳基化中间体二氢喹唑啉也被精制为三环二氢咪唑并[2,1- b ]喹唑啉酮。
[EN] POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS<br/>[FR] PYRIMIDINES POLYCYCLIQUES UTILISES EN TANT QUE MODULATEURS DU CANAL IONIQUE DU POTASSIUM
申请人:ICAGEN INC
公开号:WO2005099711A1
公开(公告)日:2005-10-27
The present invention provides a genus of polycyclic pyrimidines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.
本发明提供了一类多环嘧啶,可作为钾离子通道的调节剂。该发明的调节剂在治疗和诊断方法中均有用处。
INHIBITORS OF HEDGEHOG PATHWAY
申请人:Bahceci Suleyman
公开号:US20090105211A1
公开(公告)日:2009-04-23
The present invention is directed to a compound of Formula I
or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.